Cat. No.: HY-14532

Brincidofovir

(Synonyms: CMX001; HDP-CDV)

6 Cited Publications

Customer Review

Based on 6 publication(s) in Google Scholar

Brincidofovir (CMX001), the lipid-conjugated prodrug of Cidofovir (HY-17438), is an orally available, long-acting antiviral. Brincidofovir shows activity against a broad spectrum of DNA viruses including cytomegalovirus (CMV), adenovirus (ADV), varicella zoster virus, herpes simplex virus, polyomaviruses, papillomaviruses, poxviruses, and mixed double-stranded DNA virus infections. Brincidofovir, an oral antiviral in late stage development, has proven effective against orthopoxviruses in vitro and in vivo.

For research use only. We do not sell to patients.

Purity: 99.72%
CAS No.: 444805-28-1
Formula: C₂₇H₅₂N₃O₇P
Molecular Weight:561.69

Storage:

Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 6 months , -20°C, 1 month

Brincidofovir Chemical Structure

CAS No.: 444805-28-1

Size

Price

Stock

Quantity

Amount: USD 0.00

* Please select Quantity before adding items.

Top Publications Citing

Use of MCE Products

Fluorescent Dye

Strong Fluorescence Signal / Multi-Disciplinary Applications / High Fluorescence Specificity

Biological Activity
- Description
- IC₅₀ & Target
- Cellular Effect
- In Vivo
- Clinical Trial
Chemical Information
Publications (6)
Solvent & Solubility
- In Vitro
Purity & Documentation
References
Help & FAQs
Classifications
Bioz

Biological Activity

Description

IC₅₀ & Target

EC50: 5.5 nM (anti-CMV, in PDA at 7 dpi)

All HSV Isoforms :

Cellular Effect

Cell Line	Type	Value	Description	References
A549	CC₅₀	20.07 μM Compound: BCV; HDP-CV, CMX001	Cytotoxicity against human A549 cells incubated for 72 hrs by neutral red based spectrophotometric analysis Cytotoxicity against human A549 cells incubated for 72 hrs by neutral red based spectrophotometric analysis	[PMID: 37390509]
BSC-1	CC₅₀	25.3 μM Compound: 1, HDP-CDV	Cytotoxicity against african green monkey BSC1 cells after 2 to 4 hrs by MTS assay Cytotoxicity against african green monkey BSC1 cells after 2 to 4 hrs by MTS assay	[PMID: 21493074]
BSC-1	EC₅₀	0.125 μM Compound: 1, HDP-CDV	Antiviral activity against Ectromelia virus Moscow infected in african green monkey BSC1 cells after 4 to 5 days by plaque reduction assay Antiviral activity against Ectromelia virus Moscow infected in african green monkey BSC1 cells after 4 to 5 days by plaque reduction assay	[PMID: 21493074]
HFF	EC₅₀	0.06 μM Compound: HDP-CDV	Antiviral activity against Cowpox virus Brighton replication in HFF cells Antiviral activity against Cowpox virus Brighton replication in HFF cells	[PMID: 16539388]
HFF	EC₅₀	0.08 μM Compound: HDP-CDV	Antiviral activity against Vaccinia virus Copenhagen replication in HFF cells Antiviral activity against Vaccinia virus Copenhagen replication in HFF cells	[PMID: 16539388]
HFF	CC₅₀	42 μM Compound: CMX001	Cytotoxicity against HFF cells after 7 days by neutral red assay Cytotoxicity against HFF cells after 7 days by neutral red assay	[PMID: 17724153]
HFF	EC₅₀	0.13 μM Compound: CMX001	Antiviral activity against Vaccinia virus WR in HFF cells assessed as reduction plaque formation after 3 days Antiviral activity against Vaccinia virus WR in HFF cells assessed as reduction plaque formation after 3 days	[PMID: 17724153]
HFF	EC₅₀	0.14 μM Compound: CMX001	Antiviral activity against Vaccinia virus Copenhagen in HFF cells assessed as reduction plaque formation after 3 days Antiviral activity against Vaccinia virus Copenhagen in HFF cells assessed as reduction plaque formation after 3 days	[PMID: 17724153]
HFF	EC₅₀	0.24 μM Compound: CMX001	Antiviral activity against Cowpox virus Brighton in HFF cells assessed as reduction plaque formation after 3 days Antiviral activity against Cowpox virus Brighton in HFF cells assessed as reduction plaque formation after 3 days	[PMID: 17724153]
HFF	CC₅₀	31 μM Compound: HDP-CDV	Cytotoxicity against HFF cells after 7 days Cytotoxicity against HFF cells after 7 days	[PMID: 17846137]
HFF	EC₅₀	0.6 μM Compound: HDP-CDV	Antiviral activity against Cowpox virus Brighton in HFF cells assessed as reduction of viral replication after 3 days Antiviral activity against Cowpox virus Brighton in HFF cells assessed as reduction of viral replication after 3 days	[PMID: 17846137]
HFF	EC₅₀	0.8 μM Compound: HDP-CDV	Antiviral activity against Vaccinia virus Copenhagen in HFF cells assessed as reduction of viral replication after 3 days Antiviral activity against Vaccinia virus Copenhagen in HFF cells assessed as reduction of viral replication after 3 days	[PMID: 17846137]
HFF	EC₅₀	1.1 μM Compound: HDP-CDV	Antiviral activity against Vaccinia virus WR in HFF cells assessed as reduction of viral replication after 3 days Antiviral activity against Vaccinia virus WR in HFF cells assessed as reduction of viral replication after 3 days	[PMID: 17846137]
HFF	CC₅₀	25 μM Compound: 1, HDP-CDV	Cytotoxicity against human HFF cells assessed as reduction in cell viability after 7 days by neutral red uptake assay Cytotoxicity against human HFF cells assessed as reduction in cell viability after 7 days by neutral red uptake assay	[PMID: 21493074]
HFF	EC₅₀	0.08 μM Compound: 1, HDP-CDV	Antiviral activity against Vaccinia virus Copenhagen infected in human HFF cells after 3 days by plaque reduction assay Antiviral activity against Vaccinia virus Copenhagen infected in human HFF cells after 3 days by plaque reduction assay	[PMID: 21493074]
HFF	EC₅₀	0.2 μM Compound: 1, HDP-CDV	Antiviral activity against Cowpox virus (Brighton Red) infected in human HFF cells after 3 days by plaque reduction assay Antiviral activity against Cowpox virus (Brighton Red) infected in human HFF cells after 3 days by plaque reduction assay	[PMID: 21493074]
HFF	EC₅₀	0.0009 μM Compound: HDP (S)-HPMPC	Antiviral activity against Human cytomegalovirus AD169 infected in HFF cells assessed as protection against virus-induced cytopathicity Antiviral activity against Human cytomegalovirus AD169 infected in HFF cells assessed as protection against virus-induced cytopathicity	[PMID: 21565516]
HFF	EC₅₀	0.9 nM Compound: HDP (S)-HPMPC	Antiviral activity against Human cytomegalovirus AD169 infected in HFF cells assessed as protection against virus-induced cytopathicity Antiviral activity against Human cytomegalovirus AD169 infected in HFF cells assessed as protection against virus-induced cytopathicity	[PMID: 21565516]
Vero	CC₅₀	13.87 μM Compound: BCV; HDP-CV, CMX001	Cytotoxicity against African green monkey Vero cells incubated for 72 hrs by neutral red based spectrophotometric analysis Cytotoxicity against African green monkey Vero cells incubated for 72 hrs by neutral red based spectrophotometric analysis	[PMID: 37390509]

In Vivo

Brincidofovir (BCV) (20 mg/kg; p.o.; on days 1, 3, 5, 7, 10, 14, 17, 21, and 24) extends survival in immune-deficient BALB/c nu/nu mice following lethal challenge with IHD-J-Luc VACV^[3].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:

BALB/c nu/nu mice (infected with IHD-J-Luc VACV)^[3]
Dosage:

20 mg/kg
Administration:

P.o.; on days 1, 3, 5, 7, 10, 14, 17, 21, and 24
Result:

On days 1, 3, and 5 maintained their weights initially but started to lose weight beginning on day 9 and succumbed between days 24 and 29 postchallenge.

Clinical Trial

NCT Number	Sponsor	Condition	Start Date	Phase A549
NCT01329991	Plexxikon\|		2011-05	PHASE1

Chemical Information

CAS No. 444805-28-1
Appearance Solid
Molecular Weight 561.69
Formula C₂₇H₅₂N₃O₇P
Color White to off-white
SMILES

NC1=NC(N(C[C@@H](CO)OCP(O)(OCCCOCCCCCCCCCCCCCCCC)=O)C=C1)=O
Synonyms

CMX001; HDP-CDV
Shipping

Room temperature in continental US; may vary elsewhere.

Storage

Powder	-20°C	3 years
	4°C	2 years
In solvent	-80°C	6 months
	-20°C	1 month

Publications (6)

All

Sort by:

Journal Impact Factor

Emerg Microbes Infect

Assessment of three antiviral compounds against Borealpox virus infection in a mouse model. [Abstract]

2026 Dec;15(1):2623694. PMID: 41591827
Emerg Microbes Infect

The assessment on cross immunity with smallpox virus and antiviral drug sensitivity of the isolated mpox virus strain WIBP-MPXV-001 in China. [Abstract]

2023 Dec;12(1):2208682. PMID: 37128898
Pharmaceuticals (Basel)

New Assay Systems to Characterize the Broad-Spectrum Antiherpesviral and Non-Herpesviral Activity of Cyclin-Dependent Kinase (CDK) 8 Inhibitors. [Abstract]

2025 Oct 16;18(10):1560. PMID: 41155676
Antiviral Res

Artemisone demonstrates synergistic antiviral activity in combination with approved and experimental drugs active against human cytomegalovirus. [Abstract]

2019 Dec;172:104639. PMID: 31654672
Pathogens

Antiviral Efficacy of the Traditional Chinese Medicine Mixture Yuanzhixingrenheji Against Human Adenovirus-7 In Vitro, In Vivo, and in a Clinical Retrospective Study. [Abstract]

2026 Apr 24;15(5):463. PMID: 42198590
SSRN

2025 Nov 3.

Solvent & Solubility

In Vitro:

0.1 M NaOH : 50 mg/mL (89.02 mM; Need ultrasonic)

DMSO : 1 mg/mL (1.78 mM; adjust pH to 8 with NaOH and heat to 50°C; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

View the Complete Stock Solution Preparation Table

Preparing Stock Solutions

View the Complete Stock Solution Preparation Table

Concentration Solvent Mass

1 mg

5 mg

10 mg

Concentration

Solvent

Mass

1 mM

1.7803 mL

8.9017 mL

17.8034 mL

5 mM

0.3561 mL

1.7803 mL

3.5607 mL

10 mM

0.1780 mL

0.8902 mL

1.7803 mL

Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.

Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

Molarity Calculator

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass Mass

Concentration Concentration

Volume Volume

Molecular Weight Molecular Weight

Dilution Calculator

Concentration _(start) × Volume _(start) = Concentration _(final) × Volume _(final)

Concentration _(start) Concentration _(start)

Volume _(start) Volume _(start)

Concentration _(final) Concentration _(final)

Volume _(final) Volume _(final)

Purity & Documentation

Select Batch:

Purity: 99.98%

Assay: 99.98%

ee.: 99.98%

Data Sheet (270 KB)
SDS (394 KB)
- English - EN (394 KB)
- Français - FR (394 KB)
- Deutsch - DE (394 KB)
- Norwegian - NO (394 KB)
- Español - ES (394 KB)
- Swedish - SV (394 KB)
- Italian - IT (394 KB)
- Korean - KR (394 KB)
- Portuguese - PT (394 KB)
COA (2659 KB)
Elemental Analysis Report (2659 KB)
HNMR (2659 KB)
CNMR (2659 KB)
RP-HPLC (2659 KB)
NP-HPLC (2659 KB)
MS (2659 KB)
LCMS (2659 KB)
IR (2659 KB)
GC (2659 KB)
OR (2659 KB)
SDS-PAGE (2659 KB)
SEC-HPLC (2659 KB)
Other Report (2659 KB)
Handling Instructions (2659 KB)

References

[1]. Hiwarkar P, et al. Brincidofovir is highly efficacious in controlling adenoviremia in pediatric recipients of hematopoietic cell transplant. Blood. 2017;129(14):2033-2037. [Content Brief]

[2]. Detweiler CJ, et al. Brincidofovir (CMX001) Toxicity Associated With Epithelial Apoptosis and Crypt Drop Out in a Hematopoietic Cell Transplant Patient: Challenges in Distinguishing Drug Toxicity From GVHD. J Pediatr Hematol Oncol. 2018;40(6):e364-e368. [Content Brief]

[3]. Zaitseva M, McCullough KT, Cruz S, et al. Postchallenge administration of brincidofovir protects healthy and immune-deficient mice reconstituted with limited numbers of T cells from lethal challenge with IHD-J-Luc vaccinia virus. J Virol. 2015;89(6):3295-3307. [Content Brief]

[4]. Scott A Foster , et al. The Role of Brincidofovir in Preparation for a Potential Smallpox Outbreak. Viruses. 2017 Oct 30;9(11):320. [Content Brief]

Help & FAQs

How should lyophilized recombinant proteins be reconstituted and stored?

1. Before opening the cap, centrifuge the vial at 13000 rpm for 20-30 seconds. This step will ensure that any lyophilized powder that may have adhered to the cap or walls is collected at the bottom of the vial, minimizing the risk of product loss.

Complete Stock Solution Preparation Table

Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

Optional Solvent	Concentration Solvent Mass	1 mg	5 mg	10 mg	25 mg
DMSO / 0.1 M NaOH	1 mM	1.7803 mL	8.9017 mL	17.8034 mL	44.5085 mL
0.1 M NaOH	5 mM	0.3561 mL	1.7803 mL	3.5607 mL	8.9017 mL
	10 mM	0.1780 mL	0.8902 mL	1.7803 mL	4.4509 mL
	15 mM	0.1187 mL	0.5934 mL	1.1869 mL	2.9672 mL
	20 mM	0.0890 mL	0.4451 mL	0.8902 mL	2.2254 mL
	25 mM	0.0712 mL	0.3561 mL	0.7121 mL	1.7803 mL
	30 mM	0.0593 mL	0.2967 mL	0.5934 mL	1.4836 mL
	40 mM	0.0445 mL	0.2225 mL	0.4451 mL	1.1127 mL
	50 mM	0.0356 mL	0.1780 mL	0.3561 mL	0.8902 mL
	60 mM	0.0297 mL	0.1484 mL	0.2967 mL	0.7418 mL
	80 mM	0.0223 mL	0.1113 mL	0.2225 mL	0.5564 mL

Keywords

Brincidofovir

6 Cited Publications

100 mg Get Quote

Subscribe to the

MedChemExpress

Newsletter

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent:

Product Name:
CAS No.:
Species:
Purity:
Quantity:

Brincidofovir

MCE Bioactive Compound Library

Drug Repurposing Compound Library Plus

FDA-Approved Drug Library Plus

Publications Citing Use of MedChemExpress (MCE) Brincidofovir

All HSV Isoforms

Biological Activity

Chemical Information

Publications (6)

Solvent & Solubility

Purity & Documentation

References

Help & FAQs

Complete Stock Solution Preparation Table

Brincidofovir

MCE Bioactive Compound Library

Drug Repurposing Compound Library Plus

FDA-Approved Drug Library Plus

Publications Citing Use of MedChemExpress (MCE) Brincidofovir

All HSV Isoforms

Biological Activity

Chemical Information

Publications (6)

Solvent & Solubility

Purity & Documentation

References

Help & FAQs

Complete Stock Solution Preparation Table

Brincidofovir Related Classifications

HY-14532 Related Classifications